成纖維細胞生長因子23(全長) Elisa試劑盒-FGF23 (intact) ELISA Kit代理/參數/廠家-ELISA試劑盒-艾美捷科技有限公司

PRODUCT CENTER

ELISA試劑盒

產品中心

當前位置：首頁 > 產品中心 > 免疫學產品 > ELISA試劑盒

背景資料: FGF23 (fibroblast growth factor 23) is a member of the fibroblast growth factor family and controls phosphate and vitamin D homeostasis. The full-length protein comprises 251 amino acids including a 24 amino acid signal peptide. The N-terminal FGF homology region of FGF23 is separated from the unique C-terminal region by a proteolytic cleavage site. A proportion of FG23 is proteolytically processed between arginine179 and serine180 to generate N-terminal and C-terminal fragments. Therefore, the major forms of FGF23 present in human circulation are hormonally intact FGF23 and inactive N-terminal and C-terminal fragments. FGF23 binds to FGF receptor 1c (FGFR1c) with its N-terminal region, while the C-terminal region is capable of interacting with the co-receptor αKlotho to confer high-affinity binding to the receptor. FGFR1c and αKlotho are expressed in the distal nephron and the parathyroid gland. Co-receptor independent signaling of FGF23 has been described for other FGFRs, which are expressed in a variety of tissues. The main source of FGF23 are osteocytes in the bone.

產品描述: Method Sandwich ELISA, HRP/TMB, 12×8-well detachable strips Sample type Plasma (EDTA, citrate, hepar?n), serum, urine, cell culture supernatant Sample volume 50 μl / well Assay time 3 h / 30 min Sensitivity 5.4 pg/ml (= 0.21 pmol/l) Standard range 0 – 1 600 pg/ml (= 0 – 60.8 pmol/l) Conversion factor 1 pg/ml = 0.038 pmol/l; MW: 26 kDa Specificity Endogenous and recombinant human intact FGF23. Cross-reactivity The assay does not cross-react with FGF3, FGF19, and FGF21. Precision In-between-run (n=9): ≤ 6 % CV Within-run (n=3): ≤ 8 % CV

其他: Biomedica Immunoassay(bmgrp)公司成立于1988年, 總部位于奧地利維也納，主要致力于研究、開發和生產基于ELISA方法用于臨床前研究相關標記物檢測的工具。迄今為止Biomedica Immunoassay公司在心血管檢測及骨代謝檢測領域開發了一系列特色ELISA檢測試劑盒，Biomedica Immunoassay的生產過程符合GMP/GLP指南，并符合ISO 9001:2015管理體系，有CE認證。Biomedica Immunoassay的產品根據FDA， EMEA和ICH指南進行驗證，并具有驗證報告。